A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Public ClinicalTrials.gov record NCT05154487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
Study identification
- NCT ID
- NCT05154487
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GOG Foundation
- Network
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Interventions
- Alpelisib Pill Drug
- Fulvestrant injection Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2024
- Primary completion
- Apr 30, 2028
- Completion
- Oct 31, 2028
- Last update posted
- Mar 2, 2026
2024 – 2028
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| AdventHealth Gynecologic Oncology | Orlando | Florida | 32804 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Moffit Cancer Center at International Plaza | Tampa | Florida | 33607 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Moffit Cancer Center at Wesley Chapel | Wesley Chapel | Florida | 33544 | — |
| Ascension St. Vincent | Indianapolis | Indiana | 46260 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| Johns Hopkins Medicine | Baltimore | Maryland | 21287 | — |
| Northwell Health Cancer Institute | Lake Success | New York | 11042 | — |
| QCC- Northwell Health Physicians Partners Medical | Rego Park | New York | 11374 | — |
| Kettering Health Cancer Center | Kettering | Ohio | 45429 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa | Oklahoma | 74146 | — |
| Legacy Good Samaritan Medical Center | Portland | Oregon | 97210 | — |
| Legacy Meridian Park Medical Center | Tualatin | Oregon | 97062 | — |
| Legacy Salmon Creek Medical Center | Vancouver | Washington | 98686 | — |
| University of Wisconsin Clinical Science Center | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05154487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05154487 live on ClinicalTrials.gov.